{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:59Z","timestamp":1787019599611,"version":"build-2736575974"},"reference-count":75,"publisher":"European Respiratory Society (ERS)","issue":"179","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Progressive systemic sclerosis-related interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in systemic sclerosis (Ssc). Yet, there remains no consensus definition of interstitial lung disease (ILD) progression or risk stratification tool to aid in identifying for whom and when therapeutic intervention is warranted or which patients should be included in clinical trials because they are especially at risk of progressive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to determine from the literature which variables were consistently associated with SSc-ILD and, more importantly, which have been demonstrated to be predictors of progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used two electronic databases, EMBASE and PubMed, to perform a scoping literature review of published articles on SSc-ILD, with a primary focus on ILD progression. Any variables reported to be associated with or predictive of ILD progression were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 1327 citations identified, 56 full-text articles were included in this scoping review. Most studies assessed the association of baseline variables with ILD progression and were not true assessments of the predictive value of these variables. In fact, analysis of the literature revealed a lack of a clear consensus definition for ILD progression. As such, there is a paucity of variables that can predict with confidence which patients will show ILD progression. Only one variable, the serological biomarker KL-6, was found to be consistently predictive of progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Significant knowledge gaps remain in our ability to predict individuals at risk of progressive SSc-ILD. Given the significant morbidity and mortality associated with progressive ILD, identifying these patients and their successful enrolment in clinical therapeutic trials is of the upmost importance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/16000617.0273-2024","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:35:18Z","timestamp":1768383318000},"page":"240273","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations with, and predictors of, progression in systemic sclerosis-related interstitial lung disease: a scoping literature review"],"prefix":"10.1183","volume":"35","author":[{"given":"Kathleen","family":"Morrisroe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026033102050561000_35.179.240273.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.05.003"},{"key":"2026033102050561000_35.179.240273.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068"},{"key":"2026033102050561000_35.179.240273.3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/kez532","article-title":"The clinical and economic burden of systemic sclerosis related interstitial lung disease","volume":"59","author":"Morrisroe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026033102050561000_35.179.240273.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170307"},{"key":"2026033102050561000_35.179.240273.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"2026033102050561000_35.179.240273.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370903"},{"key":"2026033102050561000_35.179.240273.7","doi-asserted-by":"publisher","DOI":"10.1186\/ar3125"},{"key":"2026033102050561000_35.179.240273.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026033102050561000_35.179.240273.9","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.3390\/jcm11154631","article-title":"new era in systemic sclerosis treatment: recently approved therapeutics","volume":"11","author":"Ebata","year":"2022","journal-title":"J Clin Med"},{"key":"2026033102050561000_35.179.240273.10","unstructured":"US Food and Drug Administration . Surrogate Endpoint Resources for Drug and Biological Development. https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development Date last updated: 24 July 2018."},{"key":"2026033102050561000_35.179.240273.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108497"},{"key":"2026033102050561000_35.179.240273.12","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"2026033102050561000_35.179.240273.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b375"},{"key":"2026033102050561000_35.179.240273.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026033102050561000_35.179.240273.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2026033102050561000_35.179.240273.16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026033102050561000_35.179.240273.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.033"},{"key":"2026033102050561000_35.179.240273.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev016"},{"key":"2026033102050561000_35.179.240273.19","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319889549"},{"key":"2026033102050561000_35.179.240273.20","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200499"},{"key":"2026033102050561000_35.179.240273.21","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/rheumatology\/kead491","article-title":"Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease","volume":"63","author":"Morrisroe","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026033102050561000_35.179.240273.22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/acr2.11598","article-title":"Combining clinical and biological data to predict progressive pulmonary fibrosis in patients with systemic sclerosis despite immunomodulatory therapy","volume":"5","author":"Volkmann","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2026033102050561000_35.179.240273.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026033102050561000_35.179.240273.24","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts","volume":"69","author":"Wu","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026033102050561000_35.179.240273.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.30467"},{"key":"2026033102050561000_35.179.240273.26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11398","article-title":"The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis","volume":"4","author":"Jandali","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026033102050561000_35.179.240273.27","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/rheumatology\/keac639","article-title":"Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort","volume":"62","author":"Ramahi","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026033102050561000_35.179.240273.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker333"},{"key":"2026033102050561000_35.179.240273.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.02.015"},{"key":"2026033102050561000_35.179.240273.30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","article-title":"Frequency of circulating topoisomerase-I-specific CD4\u2005T cells predicts presence and progression of interstitial lung disease in scleroderma","volume":"18","author":"Fava","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026033102050561000_35.179.240273.31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-023-03141-4","article-title":"Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study","volume":"25","author":"Hamberg","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026033102050561000_35.179.240273.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088150"},{"key":"2026033102050561000_35.179.240273.33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/jcm10040660","article-title":"Serum TARC levels in patients with systemic sclerosis: clinical association with interstitial lung disease","volume":"10","author":"Kuzumi","year":"2021","journal-title":"J Clin Med"},{"key":"2026033102050561000_35.179.240273.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170518"},{"key":"2026033102050561000_35.179.240273.35","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41020","article-title":"Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18","volume":"71","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026033102050561000_35.179.240273.36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/resp.13988","article-title":"Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression","volume":"26","author":"Stock","year":"2021","journal-title":"Respirology"},{"key":"2026033102050561000_35.179.240273.37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026033102050561000_35.179.240273.38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120997"},{"key":"2026033102050561000_35.179.240273.39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"2026033102050561000_35.179.240273.40","first-page":"S71","article-title":"CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis","volume":"30","author":"Sfriso","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026033102050561000_35.179.240273.41","doi-asserted-by":"crossref","first-page":"152376","DOI":"10.1016\/j.semarthrit.2024.152376","article-title":"Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: a post hoc analysis from the focuSSced trial","volume":"65","author":"Bernstein","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026033102050561000_35.179.240273.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90333-0"},{"key":"2026033102050561000_35.179.240273.43","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/s10165-012-0795-6","article-title":"Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study","volume":"23","author":"Hasegawa","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2026033102050561000_35.179.240273.44","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semarthrit.2020.06.003","article-title":"The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis","volume":"50","author":"Volkmann","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026033102050561000_35.179.240273.45","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0872-2"},{"key":"2026033102050561000_35.179.240273.46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac535"},{"key":"2026033102050561000_35.179.240273.47","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026033102050561000_35.179.240273.48","first-page":"274","article-title":"Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis","volume":"36","author":"Becker","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026033102050561000_35.179.240273.49","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1007\/s10067-020-05105-4","article-title":"Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment","volume":"39","author":"Vanaken","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026033102050561000_35.179.240273.50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead234"},{"key":"2026033102050561000_35.179.240273.51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4046\/trd.2020.0043","article-title":"Short-term lung function changes and predictors of progressive systemic sclerosis-related interstitial lung disease","volume":"83","author":"Kaenmuang","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2026033102050561000_35.179.240273.52","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060209"},{"key":"2026033102050561000_35.179.240273.53","doi-asserted-by":"crossref","first-page":"e003658","DOI":"10.1136\/rmdopen-2023-003658","article-title":"Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort","volume":"10","author":"Scheidegger","year":"2024","journal-title":"RMD Open"},{"key":"2026033102050561000_35.179.240273.54","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026033102050561000_35.179.240273.55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213201"},{"key":"2026033102050561000_35.179.240273.56","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.chest.2021.11.009","article-title":"Independent association between occupational exposure and decline of FVC in systemic sclerosis: a multicenter recruitment retrospective cohort study","volume":"161","author":"Thoreau","year":"2022","journal-title":"Chest"},{"key":"2026033102050561000_35.179.240273.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.07.002"},{"key":"2026033102050561000_35.179.240273.58","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab118"},{"key":"2026033102050561000_35.179.240273.59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-018-1545-8","article-title":"Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis","volume":"20","author":"Weigold","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2026033102050561000_35.179.240273.60","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120725"},{"key":"2026033102050561000_35.179.240273.61","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170440"},{"key":"2026033102050561000_35.179.240273.62","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.3390\/jcm11175087","article-title":"Association between routine laboratory parameters and the severity and progression of systemic sclerosis","volume":"11","author":"Chikhoune","year":"2022","journal-title":"J Clin Med"},{"key":"2026033102050561000_35.179.240273.63","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160339"},{"key":"2026033102050561000_35.179.240273.64","doi-asserted-by":"crossref","first-page":"106689","DOI":"10.1016\/j.rmed.2021.106689","article-title":"Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease","volume":"191","author":"Watanabe","year":"2022","journal-title":"Respir Med"},{"key":"2026033102050561000_35.179.240273.65","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215918"},{"key":"2026033102050561000_35.179.240273.66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.reuma.2022.10.003","article-title":"Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study","volume":"19","author":"Enghelmayer","year":"2023","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2026033102050561000_35.179.240273.67","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.1038\/s41598-023-35840-y","article-title":"Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease","volume":"13","author":"Cerro-Chiang","year":"2023","journal-title":"Sci Rep"},{"key":"2026033102050561000_35.179.240273.68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10067-019-04686-z","article-title":"The predictive role of lung ultrasound in progression of scleroderma interstitial lung disease","volume":"39","author":"Gasperini","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026033102050561000_35.179.240273.69","doi-asserted-by":"crossref","first-page":"e0181692","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PLoS One"},{"key":"2026033102050561000_35.179.240273.70","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/biomedicines10092129","article-title":"Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry","volume":"10","author":"Nagy","year":"2022","journal-title":"Biomedicines"},{"key":"2026033102050561000_35.179.240273.71","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/art.41418","article-title":"Bioactive plasma mitochondrial DNA is associated with disease progression in scleroderma-associated interstitial lung disease","volume":"72","author":"Ryu","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026033102050561000_35.179.240273.72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b606"},{"key":"2026033102050561000_35.179.240273.73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078276"},{"key":"2026033102050561000_35.179.240273.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03187-2021"},{"key":"2026033102050561000_35.179.240273.75","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b604"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0273-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:05:20Z","timestamp":1774947920000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0273-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":75,"journal-issue":{"issue":"179","published-online":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/16000617.0273-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0273-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}